In spite of pretty weak top-line results, pharma companies like Merck (NYSE:MRK), Pfizer (NYSE:PFE), and Bristol-Myers (NYSE:BMY) have benefited from a relatively bullish sentiment on healthcare stocks. That sentiment may be petering out, though, and that could make it harder for Merck's stock to outperform. I believe that this company's pipeline strategy (significant quantity, but not necessarily many stars) leads to investors underestimating its potential, but I wouldn't go so far as to think it's a tremendously cheap stock today.

Another Pharma Quarter Built On Margins
Not unlike Pfizer, which also reported on Tuesday morning, Merck's quarter saw weak top-line performance compensated by relatively stronger margin results.

SEE: Pfizer Looking A Little Tired

Revenue fell 11% as reported, or 8% on an operational basis, leading to a minor (2%) miss. Pharmaceutical revenue declined 12% as reported, with slight weakness in Januvia/Janumet (up 5%) and Remicade (up 2%). Although the Januvia franchise is a significant component of revenue (more than 15%), as is the combined Vytorin/Zetia businesses (more than 11%), Merck has relatively fewer big contributors than many of its peers. Outside of drugs, animal health was down 2% and consumer health was down 11%, though the underlying performance there was actually stronger than it appears.

Although Merck recaptured some lost financial momentum with better than expected margins, the absolute performance wasn't great. Gross margin declined 150 basis points, with operating income declining 22% from the year-ago period. Operating margin did beat expectations by about a point, but that would seem to be due in part to lower R&D spending – not exactly a high-qualty beat for a drug company.

Important Data Read-Outs On The Way
Merck gets a lot of flack for its pipeline, but a couple of high-profile data releases could bring a bit more positive attention. Phase 1 data on lambro (the anti-PD1 drug lambrolizumab) in lung cancer should come out in the fall, and positive data here is expected to further clarify the multi-billion dollar potential of this drug outside of melanoma. As a reminder, Bristol-Myers and Merck are early leaders in the PD-1 space, with Roche (Nasdaq:RHHBY) a little further behind but still very much in the race.

Merck is also expected to report interim data on its BACE inhibitor MK-8931 in Alzheimers late this year, and almost any Big Pharma Alzheimers drug garnering a lot of attention.

Are Valuations Keeping Merck On The Sidelines?
Earlier this year, Merck management had talked in such a way that it seemed further licensing deals or acquisitions were very much on the radar as a way of supplementing the near-term business and the long-term pipeline. Not all that much has actually happened in the interim.

Given the bull market in biotech, this isn't entirely surprising. There are certainly companies out there that could make sense – Onyx (Nasdaq:ONXX), Allergan (NYSE:AGN), and Celldex (Nasdaq:CLDX) come to mind – but valuations have gotten pretty step and it's likely a great deal more difficult to find and structure deals today that generate worthwhile long-term returns.

The Bottom Line
I don't think Merck management needs to be in any particular hurry. When the inevitable tumble in biotech valuations arrives, there will be plenty of worthwhile candidates for Merck to pick through, though I do expect some competition from other pharma rivals looking to improve their long-term growth prospects.

SEE: Evaluating Pharmaceutical Companies

In the meantime, Merck is like most pharma companies – relatively weak top-line growth prospects, but still with some potential incremental margin improvement. I do believe the Street is likely too skeptical about the company's pipeline potential, but then I also believe the Street is too bullish about Januvia. All told, I'm looking for very low revenue growth over the long term (but with the potential for upside), as well as very modest free cash flow growth. With the shares worth about $50 today, I wouldn't be in a rush to buy, but there could still be some upside for patient holders.

Disclosure – As of this writing, the author owns shares of Roche.

Related Articles
  1. Stock Analysis

    Net Neutrality: Pros and Cons

    The fight over net neutrality has become an amazing spectacle. But at its core, it's yet another skirmish in cable television's war to remain relevant.
  2. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  3. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  4. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  5. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  6. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  7. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  8. Professionals

    What to do During a Market Correction

    The market has corrected...now what? Here's what you should consider rather than panicking.
  9. Mutual Funds & ETFs

    ETF Analysis: Vanguard Mid-Cap Value

    Take an in-depth look at the Vanguard Mid-Cap Value ETF, one of the largest and most popular mid-cap funds in the U.S. equity space.
  10. Mutual Funds & ETFs

    ETF Analysis: Schwab US Broad Market

    Take an in-depth look at the Schwab U.S. Broad Market ETF, an incredibly low-cost fund based on a wide selection of the U.S. equity market.
RELATED TERMS
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  3. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  4. Earnings Per Share - EPS

    The portion of a company's profit allocated to each outstanding ...
  5. PT (Perseroan Terbatas)

    An acronym for Perseroan Terbatas, which is Limited Liability ...
  6. Ltd. (Limited)

    An abbreviation of "limited," Ltd. is a suffix that ...
RELATED FAQS
  1. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  2. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  3. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  4. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  5. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
  6. How does the role of Medicare/Medicaid affect the drugs sector in the U.S.?

    Medicare and Medicaid have enormous influence on the pharmaceutical, or drugs, sector in the United States. For instance, ... Read Full Answer >>

You May Also Like

COMPANIES IN THIS ARTICLE
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!